Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX 1411 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MDX 1411 | EXPERIMENTAL | Dose Escalation Cohorts |
| Name | Type | Description |
|---|---|---|
| MDX 1411 | BIOLOGICAL | MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total |
Inclusion Criteria: * Histologically confirmed diagnosis of RCC with clear cell component * Measurable disease * Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy * Subjects with treated brain metastases must be without magn...
Top 20 of 36 competitors
MDX 1411 is an investigational monoclonal antibody being studied for the treatment of kidney cancer, specifically clear cell kidney cancer. It is administered every 14 days with pre-medications to subjects with this condition. The drug is currently in Phase 1 clinical development.
MDX 1411 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for kidney cancer.
MDX 1411 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial for MDX 1411 has been completed.
MDX 1411 has been studied in one clinical trial with the identifier NCT00656734. This Phase 1 trial, titled 'Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer,' enrolled 27 participants in the United States and has been completed.
Yes, MDX 1411 and MDX-1411 refer to the same investigational drug. The clinical trial NCT00656734 uses the name MDX-1411 in its title, while the drug is also referred to as MDX 1411. Both names denote the same monoclonal antibody being developed for kidney cancer.